"第一次'嗑'Pr80八颗，感觉没啥效果……可以'嗑'多少啊？" "12、18、24，以此类推。" 近日，中青报·中青网记者在某社交平台上看到这样一份"加密"对话，有年轻人在网络上交流滥用处方 药的经历。 被称作"Pr80"的药物名为普瑞巴林，本是治疗神经性疼痛的处方药，却被一些人用来追求"快感和刺 激"。为了规避监管，他们将普瑞巴林音译为"Pr80"，以"嗑"表示"吃"的意思。 普瑞巴林等处方药滥用存在哪些风险？如何为处方药滥用"踩刹车"？记者对此展开调查。 最开始吃是想"尝鲜" 00后王萌第一次接触普瑞巴林，是在一家酒吧里。 2023年年初，在一家摇滚风格的酒吧内，她和朋友聊天时，有人掏出一个纸包，里面装着一些绿色胶 囊，那人说这是普瑞巴林，要分给众人。 王萌此前过量服用过处方药右美沙芬，对对方递来的东西"心领神会"。为了"尝鲜"，她吃了两颗。 当时，王萌独自在外租房，"每天熬通宵，日子过得很空虚"。她开始在电商平台购买，一次吃4-6颗。 "药效来得慢，要等几个小时。吃了之后，特别想跟人说话，就在网上到处找人聊天。" 她觉得一个人在家用右美沙芬不太合适，容易出危险。 家住沈阳的00后赵鹏曾一度滥用普瑞巴林 ...

Core Insights - The article discusses "memory pain," a condition that can arise after the healing of shingles, known as postherpetic neuralgia (PHN) [1][2][3] Group 1: Understanding Memory Pain - Memory pain can begin 1 to 3 months after shingles has healed, despite the virus being cleared by the immune system [1] - The damage to the nerves caused by shingles leads the brain to misinterpret normal sensations as pain, resulting in various pain types such as sharp, burning, and allodynia [1] Group 2: Risk Factors and Prevention - Individuals over 60 years old, those with severe acute rashes, and those experiencing intense pain during the acute phase are at higher risk for developing PHN [1] - The optimal time to prevent PHN is during the acute phase of shingles, where early and adequate antiviral treatment within 72 hours is crucial [1][2] Group 3: Treatment Approaches - For chronic pain, a combination of oral medications like gabapentin and pregabalin, as well as topical treatments like lidocaine patches, can be effective [2] - If medication is insufficient, minimally invasive interventions such as nerve block therapy can be employed to directly target the damaged nerves [2]

Core Viewpoint - The report highlights the financial performance and growth potential of Ningbo Menovo Pharmaceutical Co., Ltd. for the first half of 2025, showcasing significant increases in revenue and net profit, alongside strategic developments in the pharmaceutical industry [1][3]. Financial Performance - The company achieved a revenue of approximately 677.33 million yuan, representing an 11.42% increase compared to the same period last year [3]. - The total profit reached approximately 60.30 million yuan, marking a substantial increase of 117.00% year-on-year [3]. - The net profit attributable to shareholders was approximately 49.06 million yuan, reflecting a remarkable growth of 158.97% compared to the previous year [3]. - The net cash flow from operating activities was negative at approximately -6.93 million yuan, an improvement from -44.47 million yuan in the previous year [3]. Industry Overview - The global pharmaceutical market is projected to reach a size of 1.9 trillion USD by 2027, driven by economic growth, aging populations, and increasing health demands [5]. - The CDMO (Contract Development and Manufacturing Organization) market is expected to grow significantly, with a forecasted size of 124.3 billion USD by 2025 and 231 billion USD by 2030, reflecting a compound annual growth rate of 13.2% [5][6]. - The Chinese CDMO industry is anticipated to reach a market size of 104.88 billion yuan by 2024, with a continued growth trend into 2025 [6]. Business Strategy - The company focuses on a vertical integration strategy encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and formulations, aiming to enhance its competitive edge in the market [11][20]. - The company has established long-term partnerships with renowned pharmaceutical firms, enhancing its market presence and operational stability [10][11]. - The company is actively expanding its CDMO services, aiming to create a comprehensive service platform to support future growth [11]. Innovation and Development - The company is committed to technological innovation, with ongoing projects in continuous flow, enzyme catalysis, and automation to improve efficiency and reduce costs [16][17]. - The company has a robust pipeline of over 50 formulation projects, with several products already approved for market entry [14]. - The company is also exploring new therapeutic areas, including weight management and metabolic health, to diversify its product offerings [13]. Regulatory Environment - The regulatory landscape is evolving, with policies aimed at enhancing drug quality and innovation, which is expected to benefit the pharmaceutical industry in the long term [9][8]. - The company has successfully passed multiple audits and inspections from international regulatory bodies, ensuring compliance with global quality standards [20]. Market Position - The company is recognized as one of the top pharmaceutical manufacturers in China, with a strong reputation for quality and reliability in the production of specialty APIs and formulations [11][20]. - The company is strategically positioned to leverage the growing demand for high-quality generic and innovative drugs in both domestic and international markets [11].

Financial Performance - The company's net profit for the first half of 2025 is projected to be between 100 million and 135 million CNY, representing an increase of 237.95% to 356.24% compared to the same period last year [2] - The net profit after deducting non-recurring gains and losses is expected to decline by 1.9 million to 3.5 million CNY, a decrease of 70.96% to 84.23% year-on-year [2][3] - The fair value changes of financial assets resulted in a significant gain of approximately 110 million CNY in the first half of the year [3] Product Development and Innovation - Key innovative drugs in development include DT678, MBT-1608, PHP1003, PHP0101, long-acting recombinant human follicle-stimulating hormone injection, and GLP-1-Fc fusion protein [4] - The long-acting recombinant human follicle-stimulating hormone injection and GLP-1-Fc fusion protein have completed clinical trials and are about to be submitted for market approval [4] - The company has a unique anti-platelet aggregation drug developed in collaboration with a U.S. university, which is currently in Phase II clinical trials [4][5] New Product Launches - The nitroglycerin spray, as a unique dosage form in China, has significant market potential, especially for emergency use in angina and myocardial infarction [6] - The company plans to enhance marketing strategies for the nitroglycerin spray through academic conferences and collaborations with various sales channels [6] Shareholder Returns - Since its listing in 2004, the company has consistently paid cash dividends, with total dividends exceeding 2.1 billion CNY, which is more than ten times the initial fundraising amount [7] E-commerce and Sales Channels - The company has established a flagship store on JD.com, with a growing range of products available for sale [9] - The proportion of oral formulations has been increasing, prompting the company to explore new marketing models, including e-commerce [9] Investment Activities - The company holds a 55.69% stake in Beijing New Mile Health Industry Group through a partnership, which is expected to yield good returns in the future [10]

Group 1 - The company successfully passed the FDA cGMP inspection at its Badu factory from March 17 to March 21, 2025, indicating compliance with quality management systems and production environment standards required by the FDA [1][4] - The inspection covered six major systems: quality system, materials, production, packaging and labeling, facilities, and laboratory controls [1] - The FDA issued an Establishment Inspection Report (EIR) confirming that the company met the necessary requirements, which supports the company's efforts to expand into international markets [1] Group 2 - The inspection results were classified as NAI (No Action Indicated), which is a favorable outcome for the company [4] - The products involved in the inspection include active pharmaceutical ingredients such as Ipratropium, Abiraterone Acetate, and Pregabalin [4] - The successful inspection is expected to have a positive impact on the company's ability to enter and grow in global regulated markets [1]